Merit Medical Systems (NASDAQ:MMSI) Issues FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.250-4.350 for the period, compared to the consensus earnings per share estimate of 3.980. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Merit Medical Systems Trading Up 3.1%

Shares of NASDAQ:MMSI traded up $2.51 during mid-day trading on Thursday, reaching $83.35. The stock had a trading volume of 2,017,456 shares, compared to its average volume of 800,196. The firm has a 50 day simple moving average of $69.06 and a two-hundred day simple moving average of $71.71. Merit Medical Systems has a twelve month low of $59.74 and a twelve month high of $94.75. The firm has a market cap of $4.97 billion, a PE ratio of 36.08, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.10. The firm had revenue of $381.88 million during the quarter, compared to analysts’ expectations of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.86 earnings per share. On average, research analysts predict that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Canaccord Genuity Group cut their target price on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $83.00 price target on shares of Merit Medical Systems in a report on Friday, May 1st. Piper Sandler restated an “overweight” rating on shares of Merit Medical Systems in a research report on Friday, July 10th. Barrington Research reduced their target price on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a report on Monday, April 20th. Finally, Wells Fargo & Company decreased their target price on Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and an average price target of $92.80.

Insider Buying and Selling

In related news, insider Brian G. Lloyd purchased 2,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were purchased at an average price of $62.62 per share, with a total value of $125,240.00. Following the completion of the purchase, the insider owned 2,000 shares in the company, valued at $125,240. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the transaction, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. This trade represents a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.70% of the company’s stock.

Institutional Trading of Merit Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of MMSI. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems in the fourth quarter valued at about $25,000. Danske Bank A S acquired a new position in shares of Merit Medical Systems during the third quarter worth about $42,000. Quarry LP grew its holdings in shares of Merit Medical Systems by 185.9% during the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 342 shares in the last quarter. Global Retirement Partners LLC grew its holdings in shares of Merit Medical Systems by 973.6% during the fourth quarter. Global Retirement Partners LLC now owns 569 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 516 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Merit Medical Systems by 745.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after buying an additional 813 shares during the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.